Abstract 17P
Background
Triple negative (TNBC) is the most aggressive subtype of breast cancer, lacking effective targeted therapies. PARP inhibitors (PARPi) like olaparib, in combination with immune checkpoint inhibitors, stand out among the groundbreaking strategies to treat BRCA1/2 mutated TNBC but are often connected to resistance.
Methods
Western blot, coimmunoprecipitation, qPCR, immunofluorescence, proliferation and cytotoxicity assays.
Results
Our preclinical results unprecedentedly show that connexin43 (Cx43) upregulation in Cx43-null BRCA1 mutated TNBC cells, de novo resistant to PARPi olaparib, deeply resensitizes them, reducing their IC50 almost by half as well as their 2D and physiologically-appropriate 3D spheroid proliferation upon treatment with the drug. Consistent with this, olaparib therapy reduces global protein PARylation and induces significantly higher levels of DNA double-strand damage, PARP1 cleavage and caspase 3-mediated apoptosis in Cx43-restored cells, emphasizing their higher susceptibility to PARPi. Similar results were obtained under physiologically-relevant Anoikis conditions and in BRCA1 mutated ovarian cancer cells. Wild type but not Cx43-restituted cells accumulate RAD51 foci after drug treatment, denoting a potential underlying mechanism of resistance. In order to validate our proposal, an innovative extracellular vesicle-based approach was developed as an avant-garde translational strategy to efficiently deliver both Cx43 and PARPi drug to tumour cells. Combination of olaparib with Cx43-enriched vesicles distinctively enhanced olaparib efficacy against de novo resistant BRCA1 mutated TNBC cells versus the drug alone. In addition, in cocultures of patient-derived and EGFR-CAR(chimeric-antigen-receptor)-engineered natural killer (NK) cells with BRCA1 mutated TNBC cells, Cx43 restoration in tumour cells elicited a significantly higher cytotoxic NK antitumour response than wild type cells.
Conclusions
These results, protected by a EU patent, reveal Cx43 as a dual promising novel therapeutic target to increase the efficacy and to resensitize de novo resistant BRCA1 mutated TNBC to PARPi olaparib, as well as to boost NK cytotoxicity against TNBC.
Clinical trial identification
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Ministerio de Universidades, European Molecular Biology Organization, Xunta de Galicia.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2P - SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
Presenter: Radek Spisek
Session: Cocktail & Poster Display session
Resources:
Abstract
3P - Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
Presenter: Solange Peters
Session: Cocktail & Poster Display session
Resources:
Abstract
4P - Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
Presenter: Edwin Lin
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
Presenter: Jenna Voellinger
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study
Presenter: jun Cao
Session: Cocktail & Poster Display session
Resources:
Abstract
7P - Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer
Presenter: Bharat Jasani
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Targeting antiapoptotic Bcl-2 proteins with highly specific BH3 mimetics in solid tumors
Presenter: Benjamin Sobol
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - An in vivo model for therapeutic antibody efficacy evaluation: The chicken embryo’s CAM-based assay
Presenter: Yan Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
Presenter: Johnathan Arnon
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer
Presenter: Vera Evtimov
Session: Cocktail & Poster Display session
Resources:
Abstract